Related by context. All words. (Click for frequent words.) 62 BCIRG 62 randomized controlled Phase 61 registrational 61 NCCTG 61 PEG SN# 60 randomized Phase III 60 Zenvia Phase III 60 NO# [002] 60 Phase 1b trial 60 multicenter Phase III 60 multicenter Phase II 59 phase IIb clinical 59 Phase Ib II 59 registrational trial 59 Phase #/#a 59 ZYBRESTAT 58 Phase 1a clinical 58 Phase Ib study 58 multicenter Phase 58 randomized Phase 2b 58 ZYBRESTAT TM 58 Phase 2a clinical 58 Phase 1b dose escalation 58 CALGB 58 iBIO Institute 58 SUCCEED trial 57 ARVO 57 pharmacokinetic PK 57 multicenter randomized double 57 Phase Ib clinical 57 placebo controlled Phase 57 MAA submission 57 LUMINATE 57 dose escalation trial 57 phase IIa clinical 57 Tanespimycin 57 Imprime PGG 57 AVADO 57 NSABP 57 Quinamed 57 MEND CABG II 57 ganetespib 57 multicenter phase 57 HER2 positive metastatic breast 57 fosbretabulin 57 phase IIb 57 randomized multicenter 57 GAMMAGARD 57 Phase III multicenter 57 multicenter clinical 57 Phase Ib 57 LUX Lung 57 label dose escalation 57 Phase #/#a trial 57 rALLy clinical trial 56 FOLOTYN ® 56 Phase 2b 56 ILLUMINATE 56 lorcaserin Phase 56 forodesine 56 TMC# C# 56 AIR CF1 56 phase IIIb 56 elotuzumab 56 Phase IIIb clinical 56 pertuzumab 56 alvespimycin 56 ARDIS 56 viral kinetic 56 multicenter prospective 56 BiTE R 56 Phase III ALLEGRO 56 randomized Phase 56 ongoing Phase 1b 56 Blinatumomab 56 REVIVE Diabetes 56 pharmacokinetic PK study 56 Phase III psoriasis 56 APEX AMI trial 56 seliciclib CYC# 56 CRMD# 56 phase IIa 56 placebo controlled Phase III 56 LibiGel ® 56 dose escalation study 56 tanespimycin 56 Phase 2b clinical 56 ENDEAVOR IV 56 Ovarian PLCO Cancer 56 velafermin belinostat 56 Phase III ThermoDox 56 Phase IIb clinical 56 Urocortin 2 55 CLL8 55 YONDELIS 55 Phase 1b clinical 55 Acute Ischemic Stroke 55 multicenter randomized Phase 55 Phase 2a trial 55 prospective multicenter 55 phase 2a 55 oral ridaforolimus 55 BRIM2 55 Phase 2b kidney transplant 55 ZACTIMA 55 randomized Phase IIb 55 prospective multicenter randomized 55 MINDSET 55 BioNumerik 55 Phase IIIb 55 Phase IIa trial 55 PXD# 55 blinded randomized placebo controlled 55 ExCell study 55 IMA# 55 Gynecologic Oncology Group 55 Phase III randomized 55 PDX pralatrexate 55 CR# vcMMAE 55 PFO migraine 55 multicentre randomized 55 EVEREST II 55 trastuzumab DM1 T DM1 55 EchoCRT 55 neratinib 55 PREVAIL 55 Phase 2b trial 55 Phase 2b study 55 SPIRIT FIRST 55 Phase 1b 55 ponatinib 55 obatoclax 55 phase IIb trial 54 APEX PD 54 Phase #b/#a clinical 54 ENESTnd 54 AIM HIGH 54 LibiGel Phase III 54 INCB# [001] 54 phase Ib 54 PANVAC VF 54 StemEx R 54 Sym# 54 ASBMR 54 PROPEL trial 54 phase IIb study 54 TRO# 54 multicenter 54 HuMax EGFr 54 CAPRIE 54 deforolimus 54 Zenvia ™ 54 HGS# 54 relapsed refractory multiple myeloma 54 dose escalation Phase 54 Elagolix 54 IMC #B 54 pivotal Phase 54 FastTrac ® 54 Phase IIa clinical 54 Glufosfamide 54 DAPT Study 54 GetGoal Phase III 54 SABCS 54 evaluating Actimmune 54 Prostate AdenoCarcinoma Treatment 54 CIMZIA TM 54 recurrent glioma 54 AZILECT R 54 prospective multicentre 54 Phase #b/#a 54 CRLX# 54 TAPAS 54 INSPIRE Trial Phase III 54 NOX E# 54 RADIANT 54 GATTEX ® 54 placebo controlled clinical 54 lorvotuzumab mertansine 54 crizotinib PF # 54 ACCLAIM 54 APTIVUS 54 SWOG 54 dose escalation clinical 54 KRN# 54 RE LY 54 GLEQ 54 Phase 1b clinical trials 54 Archexin 54 peginesatide 54 AACR #st Annual Meeting 54 MONT BLANC 54 IL# PE#QQR 54 CLARITY study 53 Phase 2b randomized 53 Dacogen injection 53 Phase Ia 53 EXCITE 53 pharmacokinetic pharmacodynamic 53 ATTRACT 53 Genasense oblimersen sodium Injection 53 AIR CF3 53 Hsp# Inhibitor 53 NSABP B 53 Sorafenib HCC Assessment 53 pralatrexate 53 Initiated Phase 53 refractory chronic lymphocytic 53 RIBBON 53 Phase III randomized controlled 53 Zemplar Capsules 53 HCV SPRINT 53 Phase III HEAT 53 number NCT# ClinicalTrials.gov 53 ONTARGET 53 evaluating REVLIMID 53 IIa clinical 53 Phase 2a 53 Pivotal Trial 53 Phase III Clinical Trial 53 Traficet EN 53 ASSERT 53 comparing alemtuzumab 53 enzastaurin 53 perifosine KRX 53 huN# DM1 53 Phase 2b Trial 53 confirmatory Phase III 53 dose escalation phase 53 evaluating carfilzomib 53 Phase IIa 53 Phase IIb 53 axitinib 53 AIR2 Trial 53 EDEMA3 53 EXPLORE Xa 53 ZYBRESTAT fosbretabulin 53 Phase 2b Clinical Trial 53 ToGA 53 lintuzumab 53 pivotal Phase III 53 talactoferrin 53 PrevOnco ™ 53 Harry Palmin President 53 CHAMPION PCI 53 BLA submission 53 treatment naive genotype 53 International Verapamil SR 53 SCH # 53 bevirimat Study 53 HCD# [002] 53 REVIVE 53 label multicenter randomized 53 KYTHERA 53 IMiDs ® compound 53 PARTNER Trial 53 multiple ascending dose 53 CoFactor 53 RESOLUTE clinical 53 EntrepreneurshipWeek USA 53 COU AA 53 cardio renal 53 custirsen 53 Azedra 53 TACI Ig 53 celgosivir 53 Randomized Phase II 52 novel histone deacetylase 52 ENVISION 52 EORTC 52 CERVARIX 52 registrational Phase 52 AIR CF2 52 Taxotere ® 52 ICAAC IDSA 52 docetaxel Taxotere R 52 Radiation Therapy Oncology 52 double blinded randomized 52 HGS ETR1 52 Augment Injectable 52 OLYMPIA registry 52 unique alkylating agent 52 OvaRex MAb 52 PRECISE trial 52 Phase Ib clinical trials 52 DSMB 52 trastuzumab emtansine T DM1 52 randomized discontinuation trial 52 clinical pharmacology studies 52 PI3K/Akt pathway inhibitor 52 REFLEX 52 EOquin TM 52 Cutaneous T 52 pomalidomide 52 Phase III metastatic melanoma 52 placebo controlled dose escalation 52 PREOS 52 iPrEx 52 sunitinib malate 52 LEUKINE 52 PRECiSE 52 Plicera 52 evaluating tivozanib 52 multicenter multinational 52 ALN VSP Phase 52 vidofludimus 52 ATTAIN 52 DermaVir Patch 52 Denufosol 52 MEND CABG 52 dextromethorphan quinidine 52 confirmatory Phase 3 52 mapatumumab 52 ON #.Na 52 recurrent glioblastoma multiforme 52 European Sepsis Trial 52 ADVANCE PD 52 Carfilzomib 52 IASLC 52 STRIDE PD 52 GEM OS1 52 Phase III pivotal 52 GELA 52 MERLIN TIMI 52 GRANT PROGRAM 52 Clinical Antipsychotic Trials 52 Patient Registry 52 ixabepilone 52 tolerated dose MTD 52 Inhalation Solution 52 BrachySil TM 52 VITAL Trial 52 Phase IIB 52 multicenter placebo controlled 52 HCV Protease Inhibitor 52 NCT# 52 ofatumumab 52 sNDA submission 52 Dr. Siegall 52 Tesetaxel 52 AASLD 52 ELACYT 52 CALGB # [002] 52 PROTEGE 52 Personalized Immunotherapy 52 MYTHOS trial 52 ascending dose 52 CUSTOM II 52 Phase III clinical 52 antibody MAb 52 bevacizumab Avastin ® 52 multicenter randomized 52 ADOPT 52 safety tolerability pharmacokinetic 52 refractory CLL 52 APPRAISE 52 TLK# 52 Group RTOG 52 Prospective Randomized 52 romidepsin 52 VEITHsymposium 52 MoxDuo IR 52 Randomized Evaluation 52 ASCO Breast Cancer 52 treatment naïve genotype 52 brivaracetam 52 HORIZONS 52 multicenter randomized placebo controlled 52 histone deacetylase HDAC inhibitor 52 colesevelam HCl 52 PRTX 52 Cardiac Allograft Rejection 52 HDAC Inhibitor 52 varespladib 51 VALOR 51 LEVADEX ™ 51 ID NCT# 51 ROCKET AF 51 By JENNIFER LEARN 51 controlled multicenter Phase 51 label multicenter Phase 51 budesonide MMX ® 51 ABSORB trial 51 nab paclitaxel 51 Phase 2a clinical trials 51 NSABP C 51 sapacitabine 51 Bezielle 51 RTOG 51 blind randomized placebo 51 ALN TTR 51 JAK1 51 Acute Decompensated Heart Failure 51 BAY #-# 51 REALISM 51 evaluating mipomersen 51 BLP# Liposome Vaccine 51 REALITY Trial 51 BR.# 51 BRIM3 51 Phase 2a preventative 51 Multicentre 51 sodium Injection 51 refractory multiple myeloma 51 EMERGE 51 controlled multicenter 51 satraplatin Phase 51 Allovectin 7 ® 51 ofatumumab HuMax CD# 51 IIa trial 51 randomized placebo controlled 51 MOTIVATE 51 Teplizumab 51 FNIH 51 prospective randomized multicenter 51 CEQ# 51 REVEAL Registry 51 Panzem R 51 sorafenib Nexavar 51 refractory cutaneous T 51 Tarceva TM 51 OZURDEX 51 HuMax CD4 51 SYMMETRY trial 51 investigational pan BCR 51 placebo controlled randomized 51 glufosfamide 51 virus HCV protease inhibitor 51 IMGN# 51 Clavis Pharma 51 3 registrational trial 51 PrevOnco 51 Oral Fingolimod 51 Alzhemed TM 51 ENDEAVOR clinical 51 subcutaneous formulation 51 VALOR trial 51 ThermoDox 51 assessing T DM1 51 plus Copegus R 51 Phase IIb III 51 oral deforolimus 51 IMC A# 51 ThermoDox ® 51 MIST II 51 Successfully Completes Phase 51 enroller 51 PRECISE 51 metastatic hormone refractory 51 EFAPROXYN 51 Phase IIb trials 51 trastuzumab Herceptin R 51 prospective randomized placebo 51 Initiate Phase 51 Genz # 51 YONDELIS R 51 TASKi2 51 HORIZONS AMI trial 51 randomized controlled multicenter 51 rNAPc2 51 TG MV 51 Xcellerated T Cells 51 unblind 51 REG2 51 CINTREDEKIN BESUDOTOX 51 cell lymphoma CTCL 51 MKC# MKC# PP 51 FDA Approvable Letter 51 VICTOR E1 51 Asthma Intervention 51 Allovectin 7 R 51 novel oral anticoagulant 51 Delcath Phase III 51 Chemophase 51 Intervention Effectiveness 51 NIH SBIR 51 CIMZIA TM certolizumab pegol 51 Phase IIb clinical trials 51 Solid Tumors 51 telomerase inhibitor drug 51 Multicenter Phase 51 SinuNase ™ 51 MSED 51 COSIRA trial 51 PSMA ADC 51 standard chemotherapy regimen 51 ASGT 51 MOZOBIL 51 ACRIN 51 depsipeptide 51 Stenting Trial 51 Therapeutics TCT 51 pharmacokinetics PK 51 Prostate Lung Colorectal 51 pivotal bioequivalence 51 cutaneous T 51 OPT CHF 51 QLT# 51 telaprevir dosed 51 INFORM 51 PEGylated interferon beta 1a 51 dasatinib Sprycel ® 50 Liprostin 50 visit www.skincancer.org 50 Hedgehog antagonist 50 REVLIMID lenalidomide 50 HGS ETR2 50 adjuvant endocrine therapy 50 NABTT 50 Phase Ib Clinical Trial 50 Tarvacin TM 50 Phase IIb Clinical Trial 50 vascular disrupting agent 50 PERSEUS 50 Clinicaltrials.gov 50 synthetic retinoid 50 EURIDIS 50 PRECEDENT 50 sorafenib tablets 50 MelaFind pivotal 50 Phase IIb Trial 50 ACTEMRA TM 50 OncoGel 50 Granted Orphan Drug 50 Phase 1a 50 iBIO 50 ACTEMRA 50 Azixa 50 Matrix Phase 2b 50 MAGE A3 ASCI 50 novel VDA molecule 50 label multicenter 50 trodusquemine 50 acyclovir Lauriad R 50 lymphoma CTCL 50 thorough QT 50 Alocrest 50 Vascugel ® 50 investigational hepatitis C 50 mitogen activated ERK kinase 50 plus COPEGUS 50 ECASS 50 Investigational Device Exemption 50 Phenoptin 50 ascending dose study 50 PHX# 50 HepeX B TM 50 GW# [003] 50 Triolex 50 USpella 50 pharmacodynamic PD 50 interferon gamma 1b 50 NASDAQ CXSP announced 50 Phase III Psoriasis 50 oral prodrug 50 Annamycin 50 Interagency Coordinating Committee 50 RE SURGE 50 Adalimumab 50 Manja Bouman CEO 50 FAME Study 50 masked placebo controlled 50 Carotid Revascularization Endarterectomy vs. 50 NCIC CTG 50 PHASE III 50 torezolid phosphate 50 ThermoDox R 50 Phase 2b monotherapy 50 BioPharm America 50 multicentre randomized double 50 Androxal TM 50 tesmilifene 50 #nd EORTC NCI 50 Refractory Angina 50 glucokinase activator 50 fallopian tube cancers 50 Symadex 50 NASDAQ BPAX 50 Endovascular Valve Edge 50 Phase III confirmatory 50 pemetrexed Alimta 50 single ascending dose 50 Bicifadine 50 AP# [003] 50 NeuVax 50 MGCD# [001] 50 Clonicel 50 Cloretazine 50 FOLFIRI chemotherapy 50 eniluracil 50 clinical trial 50 confirmatory clinical 50 Phase Ib IIa 50 GATTEX ™ 50 NANOTECH 50 prospective randomized controlled 50 Phase III 50 DDP# 50 evaluating satraplatin 50 ASTRO Annual Meeting 50 CIBMTR 50 Advanced Renal Cell 50 pralatrexate injection 50 TELCYTA 50 pegylated interferon alfa 2b 50 Inclinix 50 IMPACT IMmunotherapy 50 Podium Presentation 50 Phase 2a Clinical Trial 50 MGd 50 multicenter randomized clinical 50 viral kinetics 50 Dual Opioid 50 Nasdaq CYCC Nasdaq CYCCP 50 Ozarelix 50 AVOREN 50 GLP toxicology studies 50 metastatic castration resistant 50 prospective observational 50 StemEx 50 R roscovitine 50 HDL Selective Delipidation 50 INSPIRE 50 TAXUS IV 50 NCT# ClinicalTrials.gov 50 Onrigin 50 Connective Tissue Oncology 50 Research Traineeship 50 neoadjuvant treatment 50 IN.PACT 50 PACIFIC NORTHWEST 50 REALIZE 50 iSBTc 50 severe hypercholesterolemia 50 HepaSphere 50 safety tolerability pharmacokinetics 50 II Clinical Trial 50 Pegasys ® 50 AOSSM 50 bepotastine besilate nasal spray 50 zanolimumab 50 ABSORB clinical 50 Phase III placebo controlled 50 BRITE 50 CCX# B 50 refractory AML 50 Multicenter 50 Metabolic Efficiency 50 Æterna Zentaris 50 GATTEX TM 50 XIENCE V Stent System 50 riociguat 50 Genta Incorporated OTCBB GETA 50 ATVB 50 Immunotherapeutic 50 R#/MEM # 50 lymphoid malignancies 50 relapsed multiple myeloma 50 Ixempra 50 multicenter randomized controlled 50 Ketotransdel 50 Ceflatonin R 50 Investigational Device Exemption IDE 50 Talabostat 50 Amgen Scholars 50 blinded randomized 50 Sapacitabine 50 Cotara 50 TNFerade TM 50 eculizumab 50 Triapine 50 Ocrelizumab 50 ICON7 50 PROVENGE ® 50 STEALTH C 50 PROVENGE sipuleucel T 50 Ceflatonin 50 relapsing multiple sclerosis 50 CIMIT 50 CAMPATH 50 Amrubicin 49 Welichem 49 Phase IIb trial 49 IMPACT DCM 49 PRNewswire FirstCall Genta Incorporated 49 blind multicenter 49 preclinical efficacy 49 Omacetaxine 49 Pediatric Oncology Branch 49 omacetaxine mepesuccinate 49 immunotherapeutic vaccine 49 Recurrent Glioblastoma 49 phase IIb III 49 belinostat 49 elagolix 49 Cloretazine ® 49 albinterferon alfa 2b 49 refractory Hodgkin lymphoma 49 NCCTG N# 49 LymphoStat B TM 49 ASPIRE HIGHER 49 Aflibercept 49 ACCLAIM II 49 AVANIR Pharmaceuticals AMEX AVN 49 Nasdaq OPTR 49 Hematology Meeting 49 CCX# 49 Renal Cell Carcinoma RCC 49 LITHE 49 ASCO GU 49 randomized controlled 49 Trofex 49 CARE HF 49 Hsp# inhibitor 49 Phase III Trial 49 NOXAFIL Oral Suspension 49 perifosine 49 PNP inhibitor 49 FavId 49 leading oral taxane 49 T DM1 49 Lung Rx 49 Collegiate Inventors Competition 49 multicentre prospective 49 PEG Interferon lambda 49 HspE7 49 Aryplase 49 initiated Phase Ib 49 CRx 49 Evoltra ® 49 phase Ib clinical 49 BLA filing 49 AIMM trial 49 Late Breaker 49 NEO3 49 Diabetic Macular Edema 49 Source MDx 49 neoadjuvant 49 Double Blind Placebo 49 sipuleucel T 49 ENGAGE 49 pharmacodynamic effects 49 Phase IIa trials 49 Telatinib 49 NP2 Enkephalin 49 XL# SAR# 49 IRESSA 49 RECIST Response Evaluation Criteria 49 AZILECT ® 49 randomized double 49 Catena ® 49 Pivotal Study 49 ANTEGREN 49 eltrombopag 49 Screening Trial 49 ospemifene 49 metastatic renal cell carcinoma 49 LCP AtorFen 49 ARIKACE 49 GSK# [001] 49 Zybrestat 49 histone deacetylase inhibitor 49 TAXUS ATLAS 49 Phase III ADT 49 ARRY # 49 HPTN 49 Cardiovascular Therapeutics 49 Dr. Fahar Merchant 49 Icatibant 49 STENT 49 prospective randomized 49 PROactive Study 49 TEMSO 49 Randomized Double blind 49 DF HCC 49 Genasense ® oblimersen 49 PIX# [002] 49 XYOTAX TM 49 Daclizumab 49 SEBIO Investor Forum 49 EORTC NCI 49 GOUT 49 Developmental Therapeutics 49 TRX1 49 SEBIO 49 ENMD # 49 PERSEUS clinical program 49 MacuSight 49 ANCHOR trial 49 LigoCyte 49 GRAVITAS trial 49 Brentuximab Vedotin SGN 49 ISPOR 49 XIENCE V Everolimus Eluting 49 TiE ISB Connect 49 ISA# [002] 49 dose escalation 49 PROMACTA 49 SIMPADICO 49 elacytarabine 49 ORMD 49 Lucanix 49 plerixafor 49 Hepatocellular Carcinoma 49 CA4P 49 Drug Eluting Stent System 49 Raptiva R 49 TRISENOX 49 L BLP# 49 FOLFOX6 chemotherapy regimen 49 NeuroStar TMS Therapy 49 Controlled Trial 49 Augment Injectable Bone Graft 49 RG# ITMN 49 CAMMS# 49 EndoTAG TM -1 49 GLPG# 49 docetaxel Taxotere ® 49 National Surgical Adjuvant 49 relapsed MCL 49 Rebif ® 49 Elan NanoCrystal 49 Fracture Intervention Trial 49 SPIRIT IV 49 hepatocellular carcinoma HCC 49 TMC# [002] 49 Vascugel 49 blinatumomab 49 ASGCT 49 investigational humanized monoclonal antibody 49 BOLDER II 49 ECTRIMS 49 Telavancin 49 Ophena TM 49 ORAL Sync 49 rALLy trial 49 dosing cohort 49 Investigational Drug 49 CYT# 49 UVIDEM 49 liposome injection 49 nonrandomized 49 CED Biotech 49 Systemic Sclerosis 49 Tesmilifene 49 efficacy tolerability 49 Simulect 49 afatinib 49 EINSTEIN DVT 49 Multiple Ascending Dose 49 RE COVER 49 TRANSFORMS 48 HRPC 48 Phase III Clinical Trials 48 Bellicum 48 anticancer compound 48 ASTEROID 48 vosaroxin 48 multicentre 48 ISHLT 48 Phase IIIb study 48 Randomized Phase 48 BioCamp 48 Human Proteome Organization 48 generation PNP inhibitor 48 Group ECOG 48 RE MODEL 48 FDLI 48 Hyphanox 48 Factor VIIa 48 Pirfenidone 48 PACCE trial 48 Myoblast Program 48 Allovectin 7 48 orally administered inhibitor 48 vicriviroc 48 ritonavir boosted 48 HCV RESPOND 2 48 JAK inhibitor 48 unblinding 48 Amplimexon 48 Clinical Oncology Annual Meeting 48 initiate Phase IIb 48 BioSTAR TM 48 ABRF 48 DASISION 48 DP b# 48 AmpliMed 48 randomized clinical 48 randomized multicenter trial 48 Micromet BiTE 48 receptor tyrosine kinase inhibitor 48 HORIZONS AMI 48 PIX# trial 48 ENDEAVOR III 48 PRoFESS 48 Clolar ® 48 Proellex TM 48 THALOMID 48 Doxil ® 48 reslizumab 48 FOLOTYN 48 castration resistant prostate cancer 48 voreloxin 48 Cloretazine R VNP#M 48 Pivotal Phase III 48 Left Ventricular Dysfunction 48 RSD# oral 48 HUMAN CAPITAL 48 STEDESA 48 FDA Accelerated Approval 48 Nasdaq NYMX 48 MabCampath 48 PEGylated interferon 48 azficel T 48 CBLC# 48 Tumor Microenvironment 48 Phase III Pivotal 48 Resolute DES 48 Randomized Controlled 48 Demonstrates Sustained 48 Cethrin 48 Cimzia TM 48 MDV# 48 samalizumab 48 ADVEXIN clinical 48 Amorcyte 48 trastuzumab DM1 48 double blinded placebo 48 DUROS 48 Plenaxis TM 48 fostamatinib 48 cathepsin K inhibitor 48 IND submission 48 RDEA# 48 NGX# 48 Coremetrics visit www.coremetrics.com 48 Testosterone MDTS ® 48 Marqibo 48 Inc. Nasdaq ALTH 48 PSN# [002] 48 palifosfamide Zymafos TM 48 dose cohorts 48 DDW ® 48 galiximab 48 Dr. Gulfo 48 pharmacokinetics pharmacodynamics 48 Eluting Stent 48 Nasdaq ONXX today 48 Digital Mammographic Imaging 48 Board DSMB 48 Phase II 48 Combination REOLYSIN R 48 unblinded 48 Completes Enrollment 48 plus prednisone 48 ISENTRESS 48 amrubicin 48 AEGR 48 R vitespen 48 Taxotere R 48 ENTB 48 randomized #:#:# 48 Hematide TM 48 Inhaled AAT 48 palifosfamide 48 AeroLEF TM 48 MIVI TRUST 48 Anturol TM 48 randomized multicentre 48 AND EDUCATION 48 preclinically 48 STELLAR 48 unstable angina UA 48 stage IIIB 48 dacetuzumab 48 imetelstat GRN#L 48 CIMZIA ™ 48 placebo controlled 48 Ophena 48 abstracts summarizing 48 Digestive Diseases Week 48 Aplidin R 48 phase III ACCLAIM 48 Ranolazine 48 GRN#L 48 Sidec 48 Phase III VISTA 48 ACOMPLIA R 48 Febuxostat 48 PREOS R 48 JZP 48 Nexavar ® 48 Platelet Inhibition 48 telaprevir dosing 48 GFT# 48 RELOVAIR ™ 48 Arimidex Tamoxifen Alone 48 PEARL SC